Treating Severe Chronic Epstein-Barr Virus (EBV) Infection With EBV Specific Cytotoxic T Lymphocytes (CTLs)

PHASE1CompletedINTERVENTIONAL
Enrollment

13

Participants

Timeline

Start Date

January 31, 2000

Primary Completion Date

December 31, 2008

Study Completion Date

December 31, 2008

Conditions
Epstein-Barr Virus Infections
Interventions
BIOLOGICAL

Intravenous injection of EBV specific CTLS

"The dose levels for this study are as follows:~Level Dose~1. 2 x 107 CTLs/m2~2. 5 x 107 CTLs/m2~3. 1 x 108 CTLs/m2~If patients have a clinical response to the first infusion defined by an improvement in the fatigue score or resolution of clinical abnormalities such as lymphadenopathy or an improvement in laboratory parameters such as a decrease in VCA titer or reduction in free EBV DNA they will be eligible to receive up to 3 additional injections of CTLs at the original dose at 3 monthly intervals."

Trial Locations (2)

77030

Texas Children's Hospital, Houston

The Methodist Hospital, Houston

All Listed Sponsors
collaborator

The Methodist Hospital Research Institute

OTHER

collaborator

Center for Cell and Gene Therapy, Baylor College of Medicine

OTHER

lead

Baylor College of Medicine

OTHER

NCT00058591 - Treating Severe Chronic Epstein-Barr Virus (EBV) Infection With EBV Specific Cytotoxic T Lymphocytes (CTLs) | Biotech Hunter | Biotech Hunter